Share Twitter LinkedIn Facebook Email Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses The Outcomes Of KEYNOTE 426 Presented At GU 2019. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Tivozanib for RCC: Unpacking Efficacy, Safety, and Dose Optimization – Bradley McGregor, MD – Dana Farber Genitourinary 3 Mins Read
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read